- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.80 Å
- Oligo State
- hetero-6-6-6-6-mer
- Ligands
- 6 x ILE- SER- GLU- VAL: POLIOVIRUS TYPE 3(Non-covalent)
- 6 x J78: (METHYLPYRIDAZINE PIPERIDINE PROPYLOXYPHENYL)ETHYLACETATE(Non-covalent)
J78.2: 17 residues within 4Å:- Chain A: I.108, T.109, Y.110, M.130, L.132, I.155, Y.157, P.179, I.181, I.192, V.194, V.197, Y.203, F.236, L.239
- Chain C: A.24, I.25
11 PLIP interactions:10 interactions with chain A, 1 interactions with chain C- Hydrophobic interactions: A:Y.110, A:Y.157, A:Y.157, A:P.179, A:I.181, A:I.192, A:V.194, A:F.236, A:F.236, C:A.24
- pi-Stacking: A:Y.203
J78.5: 17 residues within 4Å:- Chain E: I.108, T.109, Y.110, M.130, L.132, I.155, Y.157, P.179, I.181, I.192, V.194, V.197, Y.203, F.236, L.239
- Chain G: A.24, I.25
11 PLIP interactions:10 interactions with chain E, 1 interactions with chain G- Hydrophobic interactions: E:Y.110, E:Y.157, E:Y.157, E:P.179, E:I.181, E:I.192, E:V.194, E:F.236, E:F.236, G:A.24
- pi-Stacking: E:Y.203
J78.8: 17 residues within 4Å:- Chain I: I.108, T.109, Y.110, M.130, L.132, I.155, Y.157, P.179, I.181, I.192, V.194, V.197, Y.203, F.236, L.239
- Chain K: A.24, I.25
11 PLIP interactions:1 interactions with chain K, 10 interactions with chain I- Hydrophobic interactions: K:A.24, I:Y.110, I:Y.157, I:Y.157, I:P.179, I:I.181, I:I.192, I:V.194, I:F.236, I:F.236
- pi-Stacking: I:Y.203
J78.11: 17 residues within 4Å:- Chain M: I.108, T.109, Y.110, M.130, L.132, I.155, Y.157, P.179, I.181, I.192, V.194, V.197, Y.203, F.236, L.239
- Chain O: A.24, I.25
11 PLIP interactions:1 interactions with chain O, 10 interactions with chain M- Hydrophobic interactions: O:A.24, M:Y.110, M:Y.157, M:Y.157, M:P.179, M:I.181, M:I.192, M:V.194, M:F.236, M:F.236
- pi-Stacking: M:Y.203
J78.14: 17 residues within 4Å:- Chain Q: I.108, T.109, Y.110, M.130, L.132, I.155, Y.157, P.179, I.181, I.192, V.194, V.197, Y.203, F.236, L.239
- Chain S: A.24, I.25
11 PLIP interactions:10 interactions with chain Q, 1 interactions with chain S- Hydrophobic interactions: Q:Y.110, Q:Y.157, Q:Y.157, Q:P.179, Q:I.181, Q:I.192, Q:V.194, Q:F.236, Q:F.236, S:A.24
- pi-Stacking: Q:Y.203
J78.17: 17 residues within 4Å:- Chain U: I.108, T.109, Y.110, M.130, L.132, I.155, Y.157, P.179, I.181, I.192, V.194, V.197, Y.203, F.236, L.239
- Chain W: A.24, I.25
11 PLIP interactions:10 interactions with chain U, 1 interactions with chain W- Hydrophobic interactions: U:Y.110, U:Y.157, U:Y.157, U:P.179, U:I.181, U:I.192, U:V.194, U:F.236, U:F.236, W:A.24
- pi-Stacking: U:Y.203
- 6 x MYR: MYRISTIC ACID(Covalent)
MYR.3: 11 residues within 4Å:- Chain D: G.1, A.2, I.29, Y.31
- Chain H: A.2, V.4, T.27, T.28, I.29, Y.31
- Ligands: MYR.6
5 PLIP interactions:2 interactions with chain D, 3 interactions with chain H- Hydrophobic interactions: D:I.29, D:Y.31, H:A.2, H:I.29
- Hydrogen bonds: H:T.27
MYR.6: 5 residues within 4Å:- Chain H: G.1, A.2, I.29, Y.31
- Ligands: MYR.3
2 PLIP interactions:2 interactions with chain H- Hydrophobic interactions: H:I.29, H:Y.31
MYR.9: 5 residues within 4Å:- Chain L: G.1, A.2, I.29, Y.31
- Ligands: MYR.12
2 PLIP interactions:2 interactions with chain L- Hydrophobic interactions: L:I.29, L:Y.31
MYR.12: 11 residues within 4Å:- Chain L: A.2, V.4, T.27, T.28, I.29, Y.31
- Chain P: G.1, A.2, I.29, Y.31
- Ligands: MYR.9
5 PLIP interactions:3 interactions with chain L, 2 interactions with chain P- Hydrophobic interactions: L:A.2, L:I.29, P:I.29, P:Y.31
- Hydrogen bonds: L:T.27
MYR.15: 11 residues within 4Å:- Chain T: G.1, A.2, I.29, Y.31
- Chain X: A.2, V.4, T.27, T.28, I.29, Y.31
- Ligands: MYR.18
5 PLIP interactions:3 interactions with chain X, 2 interactions with chain T- Hydrophobic interactions: X:A.2, X:I.29, T:I.29, T:Y.31
- Hydrogen bonds: X:T.27
MYR.18: 5 residues within 4Å:- Chain X: G.1, A.2, I.29, Y.31
- Ligands: MYR.15
2 PLIP interactions:2 interactions with chain X- Hydrophobic interactions: X:I.29, X:Y.31
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Grant, R.A. et al., Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr.Biol. (1994)
- Release Date
- 1996-07-11
- Peptides
- POLIOVIRUS TYPE 3: AEIMQU
POLIOVIRUS TYPE 3: BFJNRV
POLIOVIRUS TYPE 3: CGKOSW
POLIOVIRUS TYPE 3: DHLPTX - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
1E
1I
1M
1Q
1U
1B
2F
2J
2N
2R
2V
2C
3G
3K
3O
3S
3W
3D
4H
4L
4P
4T
4X
4
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.80 Å
- Oligo State
- hetero-6-6-6-6-mer
- Ligands
- 6 x ILE- SER- GLU- VAL: POLIOVIRUS TYPE 3(Non-covalent)
- 6 x J78: (METHYLPYRIDAZINE PIPERIDINE PROPYLOXYPHENYL)ETHYLACETATE(Non-covalent)
- 6 x MYR: MYRISTIC ACID(Covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Grant, R.A. et al., Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr.Biol. (1994)
- Release Date
- 1996-07-11
- Peptides
- POLIOVIRUS TYPE 3: AEIMQU
POLIOVIRUS TYPE 3: BFJNRV
POLIOVIRUS TYPE 3: CGKOSW
POLIOVIRUS TYPE 3: DHLPTX - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
1E
1I
1M
1Q
1U
1B
2F
2J
2N
2R
2V
2C
3G
3K
3O
3S
3W
3D
4H
4L
4P
4T
4X
4